title: Involvement of the sigma1 receptor in inhibiting activity of fluvoxamine on marble-burying behavior: comparison with paroxetine.
abstract: In the present study, we examined the involvement of the sigma1 receptor in the inhibitory effect of the selective serotonin reuptake inhibitor (SSRI) fluvoxamine, compared with that of paroxetine, on marble-burying behavior, which is an animal model of obsessive-compulsive disorder. Sigma1 receptor agonists (+)-SKF 10047 and PRE-084 significantly inhibited marble-burying behavior. Sigma receptor antagonist BD 1047 and selective sigma1 receptor antagonist BD 1063 significantly attenuated the inhibition of marble-burying behavior by fluvoxamine. In contrast, selective sigma2 receptor antagonist SM-21 failed to affect the inhibition of marble-burying behavior by fluvoxamine. On the other hand, BD 1047 and BD 1063 had no effect on the inhibition of marble-burying behavior by paroxetine. These observations show that activation of the sigma1 receptor is a necessary component in the inhibitory effect of fluvoxamine on marble-burying behavior, and that the mechanism of its action is clearly different from that of paroxetine.
authors.affiliation: Department of Neuropharmacology, Faculty of Pharmaceutical Sciences, Fukuoka University, Fukuoka and Department of Pharmacy, Kyushu University Hospital, Fukuoka 812-8582, Japan. n-egashi@pharm.med.kyushu-u.ac.jp
authors.forename: Nobuaki
authors.initials: N
authors.lastname: Egashira
authors.forename: Satoko
authors.initials: S
authors.lastname: Harada
authors.forename: Ryoko
authors.initials: R
authors.lastname: Okuno
authors.forename: Michihiko
authors.initials: M
authors.lastname: Matsushita
authors.forename: Ryoji
authors.initials: R
authors.lastname: Nishimura
authors.forename: Kenichi
authors.initials: K
authors.lastname: Mishima
authors.forename: Katsunori
authors.initials: K
authors.lastname: Iwasaki
authors.forename: Kensuke
authors.initials: K
authors.lastname: Orito
authors.forename: Michihiro
authors.initials: M
authors.lastname: Fujiwara
mesh_terms: D000818:Animals; D001522:Behavior, Animal / Q000187:drug effects*; D001921:Brain / Q000187:drug effects* / Q000378:metabolism; D002087:Butyrates / Q000494:pharmacology; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D005029:Ethylenediamines / Q000494:pharmacology; D016666:Fluvoxamine / Q000494:pharmacology* / Q000627:therapeutic use; D008297:Male; D051379:Mice; D008813:Mice, Inbred ICR; D009025:Morpholines / Q000494:pharmacology; D009771:Obsessive-Compulsive Disorder / Q000188:drug therapy* / Q000378:metabolism / Q000523:psychology; D017374:Paroxetine / Q000494:pharmacology* / Q000627:therapeutic use; D010620:Phenazocine / Q000031:analogs & derivatives / Q000494:pharmacology; D010879:Piperazines / Q000494:pharmacology; D011619:Psychotropic Drugs / Q000494:pharmacology* / Q000627:therapeutic use; D017480:Receptors, sigma / Q000187:drug effects* / Q000378:metabolism; D017367:Selective Serotonin Reuptake Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use; D014326:Tropanes / Q000494:pharmacology; D000097605:Sigma-1 Receptor
chemical_list: D002087:Butyrates; D005029:Ethylenediamines; D016666:Fluvoxamine; D009025:Morpholines; D017374:Paroxetine; D010620:Phenazocine; D010879:Piperazines; D011619:Psychotropic Drugs; D017480:Receptors, sigma; D017367:Selective Serotonin Reuptake Inhibitors; D014326:Tropanes; D000097605:Sigma-1 Receptor; C093337:1-(2-(3,4-dichlorophenyl)ethyl)-4-methylpiperazine; C106107:sigma-2 receptor; C071738:2-(4-morpholino)ethyl-1-phenylcyclohexane-1-carboxylate; C107044:SM 21; C097963:N-(2-(3,4-Dichlorphenyl)ethyl)-N,N',N'-trimethyl-1,2-ethandiamin; C012134:SK&F 10047